Provided by Parkinson & Movement Disorder Alliance

Many new therapies are in development for Parkinson’s disease, from those grounded in the disease’s neuropathology to those repurposed from other indications. This session summarizes the status and evidence related to gene therapies, antibody-based therapies, growth factors, repurposed pharmacotherapies, and new formulations of existing medications.

Estimated time to complete activity: 60 minutes

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Evaluate the current clinical evidence supporting emerging pharmacologic and non-pharmacologic therapies for Parkinson’s disease
• Differentiate among the mechanisms of action and therapeutic targets of some key investigational agents
• Recognize patient-specific factors and disease stages that inform selection or referral for emerging therapies

Faculty

Rajesh Pahwa, MD
University of Kansas Medical Center, Director of Parkinson Foundation Center of Excellence at the University of Kansas Medical Center 

Rajesh Pahwa, M.D., is the Laverne and Joyce Rider Professor of Neurology, chief of the Parkinson's and Movement Disorder Division and director of Parkinson Foundation Center of Excellence at the University of Kansas Medical Center.

Dr. Pahwa received his medical degree at Seth G.S. Medical College, University of Bombay, India. He completed an internship in medicine at Baylor College of Medicine followed by a residency in Neurology at Baylor College of Medicine, Houston, Texas. He then completed a one-year fellowship in movement disorders at the University of Kansas Medical Center. Dr. Pahwa joined the faculty of the Department of Neurology as an instructor in 1992.

Dr. Pahwa was named the inaugural recipient of the Laverne and Joyce Rider Professorship in 2005. Dr. Pahwa is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Pahwa's research interests are centered around the various aspects of Parkinson's disease and essential tremor. He is currently involved in studies related to medical and surgical forms of therapies for Parkinson's disease and essential tremor.

In addition to publishing more than 250 peer-reviewed articles in leading neurology and movement disorder journals, he has conducted more than 250 clinical trials related to Parkinson's disease and other movement disorders. Dr. Pahwa is the co-editor of "Handbook of Parkinson's Disease," 3rd and 4th editions; "Therapy of Parkinson's Disease," 3rd edition; and "Handbook of Essential Tremor and other Tremor Disorders."

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Rajesh Pahwa, MD
• Site investigator for research supported by Abbott, AbbVie, Annovis, ASK Bio, Biogen, Bukwang, Cerevance, Cerevel, GemVax, Global Kinetics, Inhibikase, Neuroderm, Praxis, Roche, Sun Pharma, Teva, UCB, and Scion
• Speakers’ Bureau, consultant, and/or advisory board member for Abbott, AbbVie, ACADIA, Allevion, Amneal, Biogen, BioVie, CalaHealth, Kyowa, Lundbeck, Merz, Neurocrine, Ono, PhotoPharmics, Sage, Supernus, UCB, Insightec, Genentech, Jazz, and Mitsubishi Tanabe

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Leslie Cloud, MD
• Site investigator for research supported by Amneal and Intracellular Therapies
• Speakers’ Bureau, consultant, and/or advisory board member for Amneal

• Britt Stone, MD
• Speakers’ Bureau, consultant, and/or advisory board member for Boston Scientific

• Jason Rivera, MPH
• No disclosures to report

• Clarisse Goas, NP
• Principal or site investigator for research supported by AskBio
• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America

• Anissa Mitchel, LCSW
• No disclosures to report

• Kelly Papesh, DNP
• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America

• Mary Ann Chapman, PhD
• Consultant for Allergan Aesthetics

• Fernando Pagan, MD
• Site investigator for research supported by Amneal and Kyowa Kirin
• Other grant support from Medtronic
• Speakers’ Bureau, consultant, and/or advisory board member for AbbVie, Acadia, Amneal, Acorda, Kyowa Kirin, Teva, Supernus, Merz, and Neurocrine

• Yasar Torres-Yaghi, MD
• No disclosures to report

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

This activity is supported by independent medical education grants from Merz, AbbVie, Kyowa Kirin, and Mitsubishi Tanabe Pharma America.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org